Cargando…

Necrotizing fasciitis associated with sorafenib treatment

We present here a case of extensive necrotizing fasciitis during sorafenib treatment in a patient with HBV-related hepatocellular carcinoma. Despite emergent extensive surgical debridement, the patient's clinical status progressive worsened until interruption of sorafenib therapy. The patient w...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Ho Won, Yun, Seok-Joong, Kim, Wun-Jae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6695268/
https://www.ncbi.nlm.nih.gov/pubmed/31428562
http://dx.doi.org/10.1016/j.idcr.2019.e00611
_version_ 1783444005582798848
author Kang, Ho Won
Yun, Seok-Joong
Kim, Wun-Jae
author_facet Kang, Ho Won
Yun, Seok-Joong
Kim, Wun-Jae
author_sort Kang, Ho Won
collection PubMed
description We present here a case of extensive necrotizing fasciitis during sorafenib treatment in a patient with HBV-related hepatocellular carcinoma. Despite emergent extensive surgical debridement, the patient's clinical status progressive worsened until interruption of sorafenib therapy. The patient was successfully treated with temporal interruption of sorafenib therapy. To our knowledge, this is the first case report of sorafenib-associated necrotizing fasciitis. Given the life-threatening nature of the infection and the necessity for urgent intervention, clinicians should be aware of this possible adverse effect of tyrosine kinase inhibitors.
format Online
Article
Text
id pubmed-6695268
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-66952682019-08-19 Necrotizing fasciitis associated with sorafenib treatment Kang, Ho Won Yun, Seok-Joong Kim, Wun-Jae IDCases Article We present here a case of extensive necrotizing fasciitis during sorafenib treatment in a patient with HBV-related hepatocellular carcinoma. Despite emergent extensive surgical debridement, the patient's clinical status progressive worsened until interruption of sorafenib therapy. The patient was successfully treated with temporal interruption of sorafenib therapy. To our knowledge, this is the first case report of sorafenib-associated necrotizing fasciitis. Given the life-threatening nature of the infection and the necessity for urgent intervention, clinicians should be aware of this possible adverse effect of tyrosine kinase inhibitors. Elsevier 2019-07-27 /pmc/articles/PMC6695268/ /pubmed/31428562 http://dx.doi.org/10.1016/j.idcr.2019.e00611 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Kang, Ho Won
Yun, Seok-Joong
Kim, Wun-Jae
Necrotizing fasciitis associated with sorafenib treatment
title Necrotizing fasciitis associated with sorafenib treatment
title_full Necrotizing fasciitis associated with sorafenib treatment
title_fullStr Necrotizing fasciitis associated with sorafenib treatment
title_full_unstemmed Necrotizing fasciitis associated with sorafenib treatment
title_short Necrotizing fasciitis associated with sorafenib treatment
title_sort necrotizing fasciitis associated with sorafenib treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6695268/
https://www.ncbi.nlm.nih.gov/pubmed/31428562
http://dx.doi.org/10.1016/j.idcr.2019.e00611
work_keys_str_mv AT kanghowon necrotizingfasciitisassociatedwithsorafenibtreatment
AT yunseokjoong necrotizingfasciitisassociatedwithsorafenibtreatment
AT kimwunjae necrotizingfasciitisassociatedwithsorafenibtreatment